Penumbra Inc
PEN.N- Latest Trade
- trading lower140.05USD
- Change
- -2.44
- % Change
1.71%Negative
- Day Range
- 134.80 - 140.55
- 52-Week Range
- 131.88 - 292.84
As of May 25 2022. Values delayed up to 15 minutes
- Previous Close
- 142.49
- Open
- 139.32
- Volume
- 78,662.00
- 3 Month Average Trading Volume
- 5.97
- Shares Out (Mil)
- 37.68
- Market Cap
- 5,368.69
- Forward P/E
- 400.26
- Dividend Yield
- -99,999.99
Key Statistics
1.66666667 mean rating - 9 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 6.86
- Price To Book (Quarterly)
- 5.60
- Price To Cash Flow (Per Share TTM)
- 514.29
- Total Debt/Total Equity (Quarterly)
- 2.91
- Long Term Debt/Equity (Quarterly)
- 2.72
- Return On Investment (TTM)
- -0.86
- Return On Equity (TTM)
- -0.77
2021 (millions USD)
About Penumbra Inc
Company Information
Penumbra, Inc. is a global healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that focuses on medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. It has developed a product portfolio that includes seven product families within its major markets, in which its neuro products include Thrombectomy, Embolization, Access, and Neurosurgical Tools. Its vascular products include Thrombectomy and Embolization. The Company's immersive healthcare product is Immersive 3D Computer-based Technology Platform. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, and Australia.
Address
1 PenumbraALAMEDA, CA
94502-7676
United States
Industry
Medical Equipment & Supplies
Executive Leadership
- Adam Elsesser
- Chairman of the Board, President, Chief Executive Officer
- Maggie S. Yuen
- Chief Financial Officer
- Johanna Roberts
- Executive Vice President, General Counsel, Secretary
- Lambert Shiu
- Chief Accounting Officer
- Arani Bose
- Director
- Harpreet S. Grewal
- Independent Director
- Don W. Kassing
- Presiding Independent Director
- Janet Leeds
- Independent Director
- Bridget A O'rourke
- Independent Director
- Surbhi Sarna
- Independent Director
- Thomas C. Wilder
- Independent Director
Latest News
- MarketsBlackBerry, Boeing, Mastercard, Banks, COVID-19 vaccine stocks
Wall Street's main indexes rose more than 1% on Tuesday, boosted by Nike and Micron following strong earnings, while beaten-down big technology stocks bounced back from an Omicron-driven rout in the previous session.
- MarketsU.S. RESEARCH ROUNDUP Azek Company, Galera Therapeutics, Vivint Smart Home
Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Azek Company, Galera Therapeutics and Vivint Smart Home, on Wednesday.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,865.10 | -- |
| Copper | 774.30 | 0.89%Negative |
| Brent Crude Oil | 114.88 | 1.16%Positive |
| CBOT Soybeans | 1,685.75 | 0.43%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,941.48 | 0.81%Negative |
| Euro STOXX 50 | 3,656.91 | 0.26%Positive |
| FTSE 100 | 7,514.87 | 0.41%Positive |
| Nikkei 225 | 26,677.80 | 0.26%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes